ScreenerHero

VTVT vTv Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · vtvtherapeutics.com
31.01USD+3.26%Mkt Cap: 122.61M $P/E: —

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap122.61M USD
Enterprise Value286.47M USD
Revenue (TTM)36.84M USD
Gross Profit8.16M USD
Net Income (TTM)-26.97M USD
Revenue/Share3.25 USD
Last Price31.01 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees26
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.39
PEG—
EV/EBITDA-30.99
EV/Revenue7.78
P/S3.22
P/B4.74
EPS (TTM)-0.72
EPS (Forward)-4.70
52W Range
19.5047% of range44.00
52W High44.00 USD
52W Low19.50 USD
Profitability
Gross Margin22.16%
Oper. Margin-25.11%
EBITDA Margin-25.10%
Profit Margin-12.91%
ROE-41.86%
ROA-30.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.25M USD
CapEx (TTM)—
FCF Margin1.83%
FCF Yield0.55%
Net Debt-86.64M USD
Net Debt/EBITDA9.37
Balance Sheet
Debt/Equity0.00
Current Ratio12.48
Quick Ratio12.35
Book Value/Sh6.34 USD
Cash/Share6.97 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:40
Split DateNov 21, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)54.71 USD
Upside (mean)+76.4%
Target Range42.00 USD – 67.00 USD
42.00+76.4% to mean67.00
# Analysts7
Ownership
Shares Out.3.95M
Float2.16M
Insiders38.83%
Institutions40.75%
Short Interest
Short Ratio3.4d
Short % Float6.68%
Short % Out.4.05%
Shares Short160.31K
Short (prev mo.)166.00K
Technical
SMA 5032.07 (-3.3%)
SMA 20034.50 (-10.1%)
Beta0.21
S&P 52W Chg16.45%
Avg Vol (30d)41.56K
Avg Vol (10d)37.20K
Technical Indicators
RSI (14)47.9
MACD-0.5173
MACD Signal-0.5224
MACD Hist.+0.0052
BB Upper33.29 USD
BB Middle31.24 USD
BB Lower29.18 USD
BB Width13.17%
ATR (14)1.409 USD
Vol Ratio (20d)0.70x